LGI1 and encephalitis: Collectively, these findings introduce a novel, noninvasive biomarker for early detection, risk stratification, and monitoring of anti‐LGI1 encephalitis, while offering fresh insights into the metabolic mechanisms underlying pathogenesis of clinical manifestations.